Vical is testing Allovectin-7 as a treatment for melanoma that has metastasized, adding that it expects to finish enrolling patients in the trail in the next few weeks. In total, the study will include 375 patients.
Shares of Vical (Nasdaq: VICL) were up 92 cents, or 33.45 percent, to $3.67.
About EQUITIES:
Since 1951, EQUITIES Magazine has been a leading media company providing business editorial content designed to serve the needs of business leaders, professionals, institutional investors and retail investors. We are focused on business and the business of making money, not on lifestyle subjects. We publish original reporting in print and on our website, as well as select content at www.nasdaq.com. For 28 years we have hosted our own branded investor conferences that connect public company CEO’s with our loyal readers in the investment community.
Sign up for a free one-year subscription to EQUITIES Magazine
